

Technical Data

Enrichment Broth for ECO157:H7

M1599

Enrichment Broth for ECO157:H7 is used as an enrichment broth for the growth of *E. coli* O157:H7 from food and environmental samples.

Composition**

Ingredients	Gms / Litre
Casein enzymic hydrolysate	10.000
Sorbitol	10.000
Bile salts mixture	1.500
Sodium chloride	5.000
Final pH (at 25°C)	7.1±0.2

^{**}Formula adjusted, standardized to suit performance parameters

Directions

Suspend 26.5 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium completely.DO NOT AUTOCLAVE. Mix well and dispense into sterile test tubes.

Principle And Interpretation

Enrichment Broth for ECO157:H7 is based on the formulation described by Rappaport and Henigh (1). *Escherichia coli* O157:H7 has been recognized as a cause of hemorrhagic colitis (2).

Casein enzymic hydrolysate provides nitrogenous, carbonaceous compounds and other essential growth nutrients. Sorbitol is a fermentable sugar, bile salt mixture inhibits most of the gram positive organisms.

Quality Control

Appearance

Cream to yellow homogeneous free flowing powder

Colour and Clarity of prepared medium

Light yellow colouered clear solution without any precipitate

Reaction

Reaction of 2.65% w/v aqueous solution at 25°C. pH: 7.1±0.2

pН

6.90-7.30

Cultural Response

M1599: Cultural characteristics observed after an incubation at 35 - 37°C for 18 - 24 hours.

Organism	Inoculum (CFU)	Growth
Cultural Response		
Escherichia coli ATCC	50-100	luxuriant
25922		
Escherichia coli 0157:H7	50-100	luxuriant
NCTC 12900		
Enterococcus faecalis ATCC	$>=10^3$	inhibited
29212		
Enterobacter sakazakii	50-100	luxuriant
ATCC 12868		
Klebsiella pneumoniae	50-100	luxuriant
ATCC 13883		
Staphylococcus aureus	$>=10^3$	inhibited
ATCC 25923	-	

HiMedia Laboratories Technical Data

Salmonella Enteritidis ATCC 50-100 luxuriant

13076

Shigella flexneri ATCC 50-100 good

12022

Storage and Shelf Life

Store below 30°C in tightly closed container and the prepared medium at 2 - 8°C. Use before expiry date on the label.

Reference

1. Rappaport F and Henigh E., J. Clin. Path., 5:361.

2.Karmali M. A., Petric M., Lim C., et al, 1985, J. Infect. Dis., 151:775.

Revision: 2 / 2015

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia™ publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia™ Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.